Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER		PATIENT:
		Name:
Re-assessment	igh risk patients required after 3 doses tick box where appropriate)	
asplen		ansplant, or chemotherapy; pre- or post-splenectomy; or with functional ement deficiency (acquired or inherited), cochlear implants, or primary
	igh risk children	
	required after 2 doses tick boxes where appropriate)	
and	Patient is a child under 18 years for (re-)immunisation	
or		vaccinate when there is expected to be a sufficient immune response
or	With primary immune deficiencies With HIV infection	
or	O With renal failure, or nephrotic syndrome	
or	O Who are immune-suppressed following organ transpla	antation (including haematopoietic stem cell transplant)
or	O With cochlear implants or intracranial shunts	
or	O With cerebrospinal fluid leaks	
or	O Receiving corticosteroid therapy for more than two we per day or greater, or children who weigh more than 1	eks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg 0 kg on a total daily dosage of 20 mg or greater
or	O With chronic pulmonary disease (including asthma tre	ated with high-dose corticosteroid therapy)
or	O Pre term infants, born before 28 weeks gestation	
	O With cardiac disease, with cyanosis or failure	
or	O With diabetes	
or	O With Down syndrome	
or	O Who are pre-or post-splenectomy, or with functional a	splenia
	esting for primary immunodeficiency diseases tick box where appropriate)	
O For us	e in testing for primary immunodeficiency diseases, on the	recommendation of an internal medicine physician or paediatrician